AzTrials
AzTrials

Cardioplegia Solution Adverse ReactionNCT05221294

Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery.

A study testing Modified Del Nido Versus Custodiol Cardioplegia in people with Cardioplegia Solution Adverse Reaction, run by Fayoum University Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cardioplegia solutions have been considered as a corner stone for myocardial protection during cardiac surgery with cardiopulmonary bypass and cardiac arrest, it limits the metabolic activity and increases the capacity of the myocardium to withstand prolonged ischemic time, and thus it has a direct impact on surgical… Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Cardioplegia Solution Adverse Reaction
What is being tested?
Modified Del Nido Versus Custodiol Cardioplegia
Could I receive a placebo?
No, everyone receives an active treatment
How many people
58 participants
Where
1 siteEgypt
Study dates
1 Feb 2022to 30 Nov 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • patients ≥ 18 years old, scheduled for elective valve replacement surgery or coronary artery bypass grafting surgery.

Who cannot join

  • Emergency surgery.
  • Chronic kidney disease.
  • Hepatic impairment.
  • Re-do surgery.
  • Severe psychiatric illness.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Fayoum University hospital

    Al Fayyum, Faiyum Governorate, 63514

Other trials in Egypt

About this study

Official title: Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Adult Patients Undergoing Cardiac Surgery; A Prospective Randomized Double-Blinded Clinical Trial.

Cardioplegia solutions have been considered as a corner stone for myocardial protection during cardiac surgery with cardiopulmonary bypass and cardiac arrest, it limits the metabolic activity and increases the capacity of the myocardium to withstand prolonged ischemic time, and thus it has a direct impact on surgical outcomes. (1, 2) Long acting cardioplegic solutions with a single dose strategy are beneficial as they allow surgery without interruptions, reducing cross clamp time and provide more cardiac protection. (3) Custodiol (histidine- tryptophan- ketoglutarate) solution has been described in the 1970s by Bretschneider (4), and used as an alternative to hyperkalemic crystalloid solutions especially during complex cardiac surgeries, also used for organ preservation during transplant surgery. (5, 6) In the 1990s Pedro del Nido and his team introduced a new cardioplegic solution (del Nido cardioplegia) for pediatric cardiac surgeries. (7) But recently, many studies postulated its use for adults. (8) The base solution for the traditional del Nido cardioplegia is Plasma-Lyte A which is a calcium free solution and electrolyte composition similar to the extracellular fluid. (7) However Plasma-Lyte A is unavailable in many countries, this precludes its use. Some authors have advocated lactated Ringer's as a base solution instead of Plasma-Lyte A for preparing del Nido cardioplegia, now known as modified del Nido cardioplegia. (9) Custodiol and modified del Nido cardioplegia can be used in a single dose fashion with proper myocardial protection and minimal surgical interruptions. However, the literature also does not confirm the superiority of one over another. (1) Also, limited number of clinical trials compared both cardioplegic solutions directly. So, in this study we aimed to assess the efficacy of both Custodiol and modified del Nido cardioplegia in myocardial protection and clinical outcomes among adult patients undergoing cardiac surgery.

Read the detailed description

Patients will be divided into two groups with 1:1 allocation, randomized by computer generated random numbers that will be placed in separate opaque envelopes opened by study investigators at OR. MDN group (will receive modified Del Nido cardioplegia solution) and C group (will receive Custodiol cardioplegia). Participants and data collectors will be blinded with the group allocation till the end of the study.

Inclusion criteria: patients ≥ 18 years old, scheduled for elective valve replacement surgery or coronary artery bypass grafting surgery.

All patients will be preoperatively examined and investigated by complete blood count, coagulation profile, liver and kidney functions and electrolytes. Electrocardiography, chest x ray and echocardiography will be routinely done. Coronary angiography and carotid arterial duplex will be requested on demand.

Patient will be premedicated by intramuscular injection of 10mg morphine at morning of the operation. Before induction of anesthesia, a five-lead electrocardiography system will be applied to monitor heart rate, rhythm, and ST segments (leads II and V5). A pulse oximeter probe will be attached, and a peripheral venous cannula will be placed. For measurement of arterial pressure and blood sampling, a 20 G cannula will be inserted into either right or left radial artery under local anesthesia. After pre-oxygenation, general anesthesia will be induced by midazolam 2-5 mg, fentanyl (10μg/kg), propofol (3-4mg/Kg), followed by atracurium (0.5 mg/kg).

Trachea will be intubated; patients will be mechanically ventilated with oxygen in air so as to achieve normocarbia. This will be confirmed by radial arterial blood gas analysis and capnogram. An esophageal temperature probe and a urinary catheter will also be placed. For drug infusion, a triple-lumen central venous catheter will be inserted via the right internal jugular vein. Anesthesia will be maintained by inhaled Isoflurane 0.4 to 1% and atracurium infusion at a rate of 0.5 mg/kg/h for continued muscle relaxation. During extracorporeal circulation, patients will receive propofol infusion at a rate of 50-100 µ/kg/min. in addition to atracurium infusion.

Before initiation of cardiopulmonary bypass (CPB), the patients will receive intravenous heparin (300-500 units/kg body weight) to achieve an activated clotting time >480s. CPB will be instituted via an ascending aortic cannula and a two-stage right atrial cannula. Before, during (pump blood flow: 2.4l/min/m2), and after CPB, mean arterial pressure will be adjusted to exceed 60mmHg.

Surgery will be done via median sternotomy; CBP will be established via arterial cannula in the ascending aorta and venous drainage obtained via two-stage cannula in the right atrium or bicaval cannulation.

Myocardial protection:

Cardioplegic solution will be administered via antegrade technique through the aortic root or the coronary ostia accordingly. Patients will receive either Custodiol cardioplegia or modified Del Nido cardioplegia according to their allocation.

Ready Custodiol cardioplegia solution will be administered in a single dose of 25ml.kg-1 over 6-8 minutes with 4-8 oC temperature and 150-200 mmHg infusion pressure. Custodiol is a ready sterile cardioplegia composed of; sodium chloride 15 mmol/L, potassium chloride 9 mmol/L, magnesium chloride 4 mmol/L, calcium chloride 0.015 mmol/L, histidine 180 mmol/L, tryptophan 2 mmol/L, ketoglutarate 1 mmol/L and mannitol 30 mmol/L with pH 7.4-7.45 at 4°C and osmolality 310 mosmol/Kg.

Modified Del Nido cardioplegia will be prepared at OR, and lactated Ringer's solution will be used as a crystalloid base, with crystalloid: blood ratio of 4:1 and will be given with a dose of 20 ml/kg (with a maximum dose of 1000 ml) at 4 oC temperature and 200-300 mmHg administration pressure and if necessary additional dose will be given after 90 minutes of the initial dose. The composition of modified Del Nido cardioplegia will be as follows: lactated Ringer's solution 1000ml, 13 ml sodium bicarbonate (1 mEq/ ml), 16.3 ml of mannitol 20%, 4 ml magnesium 50%, 6.5 ml of lidocaine 2% and 13ml of potassium chloride (2 mEq/L).

Being tested
Modified Del Nido Versus Custodiol Cardioplegia
Keywords
Myocardial Protection, Custodiol Cardioplegia, Del Nido

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Modified Del Nido Versus Custodiol CardioplegiaDrug

    Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery

Study groups in NCT05221294
Study groupRoleWhat they receive
MDN groupExperimentalwill receive modified Del Nido cardioplegia solution
Receives: Drug: Modified Del Nido Versus Custodiol Cardioplegia
C groupExperimentalwill receive Custodiol cardioplegia
Receives: Drug: Modified Del Nido Versus Custodiol Cardioplegia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. troponin I

    troponin I at 24 hours after surgery to assess myocardial protection between the two used cardioplegia solutions.

    Measured: 24 hours after surgery

Secondary outcomes (12)
  1. The total volume of cardioplegia solution

    The total volume of cardioplegia solution

    Measured: In the first 24 hours of surgery

  2. Total cross-clamp time and total CPB time

    Total cross-clamp time and total CPB time

    Measured: In the first 24 hours of surgery

  3. Incidence of ventricular fibrillation after cross-camp removal

    side effects

    Measured: In the first 24 hours of surgery

  4. Postoperative left ventricular ejection fraction

    Postoperative left ventricular ejection fraction

    Measured: 24 hours after surgery in days

  5. Requirement of inotropes and time of discontinuation

    intraoperative

    Measured: postoperative 24 hours

  6. Troponin I at 12 hours after surgery

    Troponin I at 12 hours after surgery

    Measured: postoperative 24 hours

  7. CK-MB at 12 and 24 hours after surgery

    assessment

    Measured: 24 hours after surgery

  8. Serum lactate level at 24 hours after surgery.

    assessment

    Measured: 24 hours after surgery

  9. Incidence of postoperative AF and MI.

    assessment

    Measured: 24 hours after surgery

  10. Time for weaning from mechanical ventilation

    Time for weaning from mechanical ventilation

    Measured: 24 hours after surgery in hours

  11. ICU length of stay

    assessment

    Measured: 24 hours after surgery in days

  12. hospital length of stay

    assessment

    Measured: 24 hours after surgery in days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Feb 2022
  2. Study start1 Feb 2022
  3. Primary completion15 Nov 2023
  4. Study completion30 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
58 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05221294
Sponsor's protocol ID
R193
Status last verified
Oct 2022
First submitted
20 Dec 2021
Last updated
3 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Sanetra K, Pawlak I, Cisowski M. Del Nido cardioplegia - what is the current evidence? Kardiochir Torakochirurgia Pol. 2018 Jun;15(2):114-118. doi: 10.5114/kitp.2018.76477. Epub 2018 Jun 25.

    PubMed 30069192
  • Vivacqua A, Robinson J, Abbas AE, Altshuler JM, Shannon FL, Podolsky RH, Sakwa MP. Single-dose cardioplegia protects myocardium as well as traditional repetitive dosing: A noninferiority randomized study. J Thorac Cardiovasc Surg. 2020 May;159(5):1857-1863.e1. doi: 10.1016/j.jtcvs.2019.03.125. Epub 2019 May 11.

    PubMed 31204129
  • Abdelhady MA, Goda AS, Sayed Gomaa MS, Hamed MA, Hassan AASM. Modified Del Nido Versus Custodiol(R) Cardioplegia for Myocardial Protection in Adult Patients Undergoing Cardiac Surgery; A Prospective Randomized Double-Blinded Clinical Trial. Ann Card Anaesth. 2025 Oct 1;28(4):451-458. doi: 10.4103/aca.aca_35_25. Epub 2025 Oct 13.

    PubMed 41081689

Questions about this trial

What is this clinical trial studying?

A study testing Modified Del Nido Versus Custodiol Cardioplegia in people with Cardioplegia Solution Adverse Reaction, run by Fayoum University Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

troponin I (time frame: 24 hours after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05221294, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in